Hassager C, Bonde S K, Anderson M A, Rink H, Spelsberg T C, Riggs B L
Endocrine Research Unit, Mayo Clinic, Rochester, MN 55905.
J Bone Miner Res. 1991 May;6(5):489-93. doi: 10.1002/jbmr.5650060510.
The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519-9523, 1989). We have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 microM did not significantly increase [3H]thymidine uptake (means ranged from -19% to 38% of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor beta (3 ng/ml), bovine insulin (300 micrograms/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.
最近有报道称，降钙素原的氨基末端裂解肽（N-proCT）是一种骨细胞促分裂原（Burns DM等人，《美国国家科学院院刊》86:9519 - 9523，1989）。我们研究了N-proCT对具有成熟成骨细胞表型的正常人细胞（hOB细胞）增殖的影响。在四种不同密度接种的hOB细胞（每个实验6 - 10个细胞株）中，用浓度为1 nM至1 microM的N-proCT处理24、48或96小时，并未显著增加[³H]胸腺嘧啶核苷摄取量（平均值为对照的 - 19%至38%，无显著差异）。然而，hOB细胞对转化生长因子β（3 ng/ml）、牛胰岛素（300微克/毫升）或30%胎牛血清的处理有显著反应，在所有实验中这些作为阳性对照。在96小时进行的直接细胞计数实验中证实了[³H]胸腺嘧啶核苷摄取数据。因此，我们的数据不支持N-proCT是正常人成骨细胞有效促分裂原这一假说。
